CM Management LLC Purchases 200,000 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

CM Management LLC grew its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 40.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 700,000 shares of the biotechnology company’s stock after purchasing an additional 200,000 shares during the period. CM Management LLC’s holdings in Heron Therapeutics were worth $1,071,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in HRTX. Y Intercept Hong Kong Ltd bought a new stake in Heron Therapeutics in the 3rd quarter worth about $39,000. Capstone Investment Advisors LLC purchased a new position in shares of Heron Therapeutics in the 3rd quarter worth approximately $45,000. King Wealth Management Group grew its holdings in shares of Heron Therapeutics by 52.3% in the third quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 8,000 shares in the last quarter. Glenmede Trust Co. NA increased its position in shares of Heron Therapeutics by 49.6% during the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 10,578 shares during the last quarter. Finally, Cutter & CO Brokerage Inc. lifted its holdings in Heron Therapeutics by 69.6% during the fourth quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 13,600 shares during the period. 80.01% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Needham & Company LLC restated a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Friday, February 28th. StockNews.com lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday.

Heron Therapeutics Trading Up 1.3 %

Heron Therapeutics stock opened at $2.39 on Friday. The business’s 50 day simple moving average is $1.77 and its 200 day simple moving average is $1.73. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The company has a market cap of $364.07 million, a price-to-earnings ratio of -13.28 and a beta of 1.55.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The firm had revenue of $40.78 million for the quarter, compared to analysts’ expectations of $37.37 million. As a group, equities research analysts forecast that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.